Ifetroban - Cumberland Pharmaceuticals

Drug Profile

Ifetroban - Cumberland Pharmaceuticals

Alternative Names: BMS 18029; BMS 180291; BMS 180291A; Boxaban; CPI 211; Hepatoren; Portaban; Vasculan

Latest Information Update: 14 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Cumberland Pharmaceuticals
  • Class Antiplatelets; Heterocyclic bicyclo compounds; Oxazoles; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Hepatorenal syndrome; Portal hypertension; Systemic scleroderma
  • Discontinued Coronary thrombosis; Peripheral vascular disorders; Thrombosis

Most Recent Events

  • 03 Oct 2018 Vanderbilt-Ingram Cancer Center and Cumberland Pharmaceuticals plans a phase II trial for Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater, Recurrent) (PO, capsule) (NCT03694249)
  • 23 Jul 2018 Cumberland Pharmaceuticals completes a phase II trial in Portal hypertension (In adults, In the elderly) in USA (NCT02802228)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top